Phosphodiesterase 10A inhibitor, MP-10 (PF-2545920), produces greater induction of c-Fos in dopamine D2 neurons than in D1 neurons in the neostriatum

Neuropharmacology

Volumn 99, Issue , 2015, Pages 379-386

  Wilson, Jonathan M ^a,b   Ogden, Ann Marie L ^a   Loomis, Sally ^a   Gilmour, Gary ^a   Baucum, Anthony J ^b   Belecky Adams, Teri L ^b   Merchant, Kalpana M ^b  

^a ELI LILLY AND COMPANY   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

Basal ganglia; Huntington's disease; Parkinson's disease; Schizophrenia

Indexed keywords

2 [4 [1 METHYL 4 (4 PYRIDINYL) 3 PYRAZOLYL]PHENOXYMETHYL]QUINOLINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; PHOSPHODIESTERASE; PHOSPHODIESTERASE 10A; PROTEIN C FOS; UNCLASSIFIED DRUG; 2-((4-(1-METHYL-4-PYRIDIN-4-YL-1H-PYRAZOL-3-YL)PHENOXY)METHYL)QUINOLINE; BENZAZEPINE DERIVATIVE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; PDE10A PROTEIN, MOUSE; PDE10A PROTEIN, RAT; PHOSPHODIESTERASE INHIBITOR; PYRAZOLE DERIVATIVE; QUINOLINE DERIVATIVE; SK&F 82958;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN NERVE CELL; C57BL 6 MOUSE; CELL NUCLEUS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DORSOLATERAL STRIATUM; DORSOMEDIAL STRIATUM; ENZYME INHIBITION; IMMUNOREACTIVITY; MALE; MOUSE; NEOSTRIATUM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; RAT; TRANSGENIC MOUSE; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECTS; GENETICS; METABOLISM; NERVE CELL; PATHOLOGY; RANDOMIZATION; SPRAGUE DAWLEY RAT;

ANIMALS; BENZAZEPINES; DOPAMINE AGONISTS; DOPAMINE D2 RECEPTOR ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HALOPERIDOL; MALE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOSTRIATUM; NEURONS; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PROTO-ONCOGENE PROTEINS C-FOS; PYRAZOLES; QUINOLINES; RANDOM ALLOCATION; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2;

EID: 84939795813     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2015.08.008     Document Type: Article

References (35)

1. K.K. Ade, Y. Wan, M. Chen, B. Gloss, and N. Calakos An improved BAC transgenic fluorescent reporter line for sensitive and specific identification of striatonigral medium spiny neurons Front. Syst. Neurosci. 5 2011 32
2. M. Day, D. Wokosin, J.L. Plotkin, X. Tian, and D.J. Surmeier Differential excitability and modulation of striatal medium spiny neuron dendrites J. Neurosci. 28 2008 11603 11614
3. M. Dragunow, and R. Faull The use of c-fos as a metabolic marker in neuronal pathway tracing J. Neurosci. Methods 29 1989 261 265
4. K. Fujishige, J. Kotera, and K. Omori Striatum- and testis-specific phosphodiesterase PDE10A isolation and characterization of a rat PDE10A Eur. J. Biochem. 266 1999 1118 1127
5. R.C. Gentzel, D. Toolan, R. Roberts, A.J. Koser, M. Kandebo, J. Hershey, J.J. Renger, J. Uslaner, and S.M. Smith The PDE10A inhibitor MP-10 and haloperidol produce distinct gene expression profiles in the striatum and influence cataleptic behavior in rodents Neuropharmacology 2015 10.1016/j.neuropharm.2015.05.024
6. C.R. Gerfen The neostriatal mosaic: multiple levels of compartmental organization J. Neural Transm. Suppl. 36 1992 43 59
7. S.M. Grauer, V.L. Pulito, R.L. Navarra, M.P. Kelly, C. Kelley, R. Graf, B. Langen, S. Logue, J. Brennan, L. Jiang, E. Charych, U. Egerland, F. Liu, K.L. Marquis, M. Malamas, T. Hage, T.A. Comery, and N.J. Brandon Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia J. Pharmacol. Exp. Ther. 331 2009 574 590
8. M. Heiman, A. Schaefer, S. Gong, J.D. Peterson, M. Day, K.E. Ramsey, M. Suarez-Farinas, C. Schwarz, D.A. Stephan, D.J. Surmeier, P. Greengard, and N. Heintz A translational profiling approach for the molecular characterization of CNS cell types Cell 135 2008 738 748
9. S. Kapur, and D. Mamo Half a century of antipsychotics and still a central role for dopamine D2 receptors Prog. Neuropsychopharmacol. Biol. Psychiatry 27 2003 1081 1090
10. J.M. Kemp, and T.P. Powell The structure of the caudate nucleus of the cat: light and electron microscopy Philos. Trans. R. Soc. Lond. B Biol. Sci. 262 1971 383 401
11. R.J. Kleiman, L.H. Kimmel, S.E. Bove, T.A. Lanz, J.F. Harms, A. Romegialli, K.S. Miller, A. Willis, S. des Etages, M. Kuhn, and C.J. Schmidt Chronic suppression of phosphodiesterase 10A alters striatal expression of genes responsible for neurotransmitter synthesis, neurotransmission, and signaling pathways implicated in Huntington's disease J. Pharmacol. Exp. Ther. 336 2011 64 76
12. S. Lensu, R. Miettinen, R. Pohjanvirta, J. Linden, and J. Tuomisto Assessment by c-Fos immunostaining of changes in brain neural activity induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and leptin in rats Basic Clin. Pharmacol. Toxicol. 98 2006 363 371
13. M.M. Lewis, V.J. Watts, C.P. Lawler, D.E. Nichols, and R.B. Mailman Homologous desensitization of the D1A dopamine receptor: efficacy in causing desensitization dissociates from both receptor occupancy and functional potency J. Pharmacol. Exp. Ther. 286 1998 345 353
14. M.L. Logrip, and E.P. Zorrilla Differential changes in amygdala and frontal cortex Pde10a expression during acute and protracted withdrawal Front. Integr. Neurosci. 8 2014 30
15. P. Manu, C.U. Correll, R. van Winkel, M. Wampers, and M. De Hert Prediabetes in patients treated with antipsychotic drugs J. Clin. Psychiatry 73 2012 460 466
16. A.A. Megens, H.M. Hendrickx, M.M. Mahieu, A.L. Wellens, P. de Boer, and G. Vanhoof PDE10A inhibitors stimulate or suppress motor behavior dependent on the relative activation state of the direct and indirect striatal output pathways Pharmacol. Res. Perspect. 2 2014 e00057
17. K.M. Merchant, G.R. Hanson, and D.M. Dorsa Induction of neurotensin and c-fos mRNA in distinct subregions of rat neostriatum after acute methamphetamine: comparison with acute haloperidol effects J. Pharmacol. Exp. Ther. 269 1994 806 812
18. J. Mukherjee, B.T. Christian, T.K. Narayanan, B. Shi, and J. Mantil Evaluation of dopamine D-2 receptor occupancy by clozapine, risperidone, and haloperidol in vivo in the rodent and nonhuman primate brain using 18F-fallypride Neuropsychopharmacology 25 2001 476 488
19. A. Nishi, M. Kuroiwa, D.B. Miller, J.P. O'Callaghan, H.S. Bateup, T. Shuto, N. Sotogaku, T. Fukuda, N. Heintz, P. Greengard, and G.L. Snyder Distinct roles of PDE4 and PDE10A in the regulation of cAMP/PKA signaling in the striatum J. Neurosci. 28 2008 10460 10471
20. L.C. Parr-Brownlie, and B.I. Hyland Bradykinesia induced by dopamine D2 receptor blockade is associated with reduced motor cortex activity in the rat J. Neurosci. 25 2005 5700 5709
21. G. Paxinos, and C. Watson The Rat Brain in Stereotaxic Coordinates fifth ed. 2004 Elsevier Academic Press
22. M.L. Perreault, A. Hasbi, B.F. O'Dowd, and S.R. George The dopamine d1-d2 receptor heteromer in striatal medium spiny neurons: evidence for a third distinct neuronal pathway in Basal Ganglia Front. Neuroanat. 5 2011 31
23. E. Piccart, J.F. De Backer, D. Gall, L. Lambot, A. Raes, G. Vanhoof, S. Schiffmann, and R. D'Hooge Genetic deletion of PDE10A selectively impairs incentive salience attribution and decreases medium spiny neuron excitability Behav. Brain Res. 268 2014 48 54
24. T.M. Reed, D.R. Repaske, G.L. Snyder, P. Greengard, and C.V. Vorhees Phosphodiesterase 1B knock-out mice exhibit exaggerated locomotor hyperactivity and DARPP-32 phosphorylation in response to dopamine agonists and display impaired spatial learning J. Neurosci. 22 2002 5188 5197
25. C.J. Schmidt Inhibition of Phosphodiesterase10A for the treatment of schizophrenia: preclinical rationale and clinical evaluation [Abstract] ACNP 51st Annual Meeting 2012
26. C.J. Schmidt, D.S. Chapin, J. Cianfrogna, M.L. Corman, M. Hajos, J.F. Harms, W.E. Hoffman, L.A. Lebel, S.A. McCarthy, F.R. Nelson, C. Proulx-LaFrance, M.J. Majchrzak, A.D. Ramirez, K. Schmidt, P.A. Seymour, J.A. Siuciak, F.D. Tingley 3rd, R.D. Williams, P.R. Verhoest, and F.S. Menniti Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia J. Pharmacol. Exp. Ther. 325 2008 681 690
27. J.P. Schulke, L.A. McAllister, K.F. Geoghegan, V. Parikh, T.A. Chappie, P.R. Verhoest, C.J. Schmidt, D.S. Johnson, and N.J. Brandon Chemoproteomics demonstrates target engagement and exquisite selectivity of the clinical phosphodiesterase 10A inhibitor MP-10 in its native environment ACS Chem. Biol. 9 2014 2823 2832
28. T.F. Seeger, B. Bartlett, T.M. Coskran, J.S. Culp, L.C. James, D.L. Krull, J. Lanfear, A.M. Ryan, C.J. Schmidt, C.A. Strick, A.H. Varghese, R.D. Williams, P.G. Wylie, and F.S. Menniti Immunohistochemical localization of PDE10A in the rat brain Brain Res. 985 2003 113 126
29. S. Sharma, K. Kumar, R. Deshmukh, and P.L. Sharma Phosphodiesterases: regulators of cyclic nucleotide signals and novel molecular target for movement disorders Eur. J. Pharmacol. 714 2013 486 497
30. J.A. Siuciak, S.A. McCarthy, D.S. Chapin, R.A. Fujiwara, L.C. James, R.D. Williams, J.L. Stock, J.D. McNeish, C.A. Strick, F.S. Menniti, and C.J. Schmidt Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function Neuropharmacology 51 2006 374 385
31. J.A. Siuciak, S.A. McCarthy, D.S. Chapin, A.N. Martin, J.F. Harms, and C.J. Schmidt Behavioral characterization of mice deficient in the phosphodiesterase-10A (PDE10A) enzyme on a C57/Bl6N congenic background Neuropharmacology 54 2008 417 427
32. F. Sotty, L.P. Montezinho, B. Steiniger-Brach, and J. Nielsen Phosphodiesterase 10A inhibition modulates the sensitivity of the mesolimbic dopaminergic system to D-amphetamine: involvement of the D1-regulated feedback control of midbrain dopamine neurons J. Neurochem. 109 2009 766 775
33. C.A. Strick, L.C. James, C.B. Fox, T.F. Seeger, F.S. Menniti, and C.J. Schmidt Alterations in gene regulation following inhibition of the striatum-enriched phosphodiesterase, PDE10A Neuropharmacology 58 2010 444 451
34. S.J. Sundquist, and L.K. Nisenbaum Fast Fos: rapid protocols for single- and double-labeling c-Fos immunohistochemistry in fresh frozen brain sections J. Neurosci. Methods 141 2005 9 20
35. L.S. Wilson, and N.J. Brandon Emerging Biology of PDE10A Curr. Pharm. Des. 21 2015 378 388